ozanimod

Ozanimod (RPC-1063) (RPC1063) is a specific oral S1P Receptor 1 modulator. Ozanimod has been used in trials studying the treatment of Crohn's Disease, Ulcerative Colitis, Multiple Sclerosis, and Relapsing Multiple Sclerosis.

Ozanimod hydrochloride (RPC-1063 hydrochloride) is an orally available, selective and potent sphingosine 1-phosphate (S1P) receptor modulator that shows high affinity for S1P1 and S1P5.Ozanimod has potential anticancer activity and can be used in the study of multiple sclerosis (MS), ulcerative multiple sclerosis (UMS), and other diseases. (MS), ulcerative colitis, coronavirus infections and myelodysplasia.

RP-101075 is a etabolite of Ozanimod. It exhibits a similar specificity profile as Ozanimod at the S1P receptor family in vitro, and pharmacodynamic profile in vivo.

RP101988, the principal active metabolite of Ozanimod, is a potent and selective agonist for sphingosine-1-phosphate receptor 1 (S1PR1), exhibiting half-maximal effective concentrations (EC50s) of 0.19 nM for S1PR1 and 32.8 nM for S1PR5.

RP101442, the active metabolite of Ozanimod, is a selective and potent agonist of the sphingosine-1-phosphate receptor 1 (S1PR1), displaying EC50 values of 2.6 nM for S1PR1 and 171 nM for S1PR5.